Curanex Pharmaceuticals Inc Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jun Liu
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Jericho Plaza Jericho NY United States of America 11753
- IPO Date
- Aug 26, 2025
- CIK
- 0002025942
- Website
- curanexpharma.com
- Similar Companies
- Business
- Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company specializing in the discovery, development, and commercialization of innovative botanical drugs to treat patients suffering from inflammatory diseases. Its core products focus on botanical medicines under the Phyto-N brand targeting multiple therapeutic areas including ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (now known as metabolic dysfunction-associated steatotic liver disease), and gout. The company’s flagship botanical drug candidate, Phyto-N, is designed to modulate immune responses and is advancing toward FDA-required studies with plans for Investigational New Drug (IND) application submission in 2026 and subsequent Phase I clinical trials. Curanex operates primarily in the United States with research and development leveraging clinical evidence from over 30 years of botanical drug use in China. Founded in 2017 and headquartered in Jericho, New York, the company underwent a name change from Fordman Pharma Inc. to Curanex Pharmaceuticals Inc. in November 2023. Recent strategic developments include the June 2024 acquisition of intellectual property assets, patents, and research data from Duraviva Pharma Inc. to bolster its research capabilities, and a partnership with Strategic Investor Relations in late 2025 to enhance investor communications and market visibility. The company completed a $15 million initial public offering in 2025 to fund clinical development and general corporate purposes, advancing its pipeline toward commercialization for inflammatory disease therapies. Curanex’s botanical drug development approach aims to address significant unmet medical needs in autoimmune, metabolic, and viral infections through plant-derived pharmacological solutions.
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
Head to Head Review: Curanex Pharmaceuticals (NASDAQ:CURX) and Zomedica (OTCMKTS:ZOMDF)
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
Curanex Forms World Class Scientific Advisory Board
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours
Curanex Provides Operational Update on Key Regulatory Milestones
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement